Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADONIS-PCI
NCT04695106Phase 4Recruiting
- Sponsor
- Medical University of Gdańsk
- Start
- Oct 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) and Atrial fibrillation (AFib) (2 arms), sponsored by Medical University of Gdańsk. Primary endpoint: First major or clinically relevant non-major bleeding event at 24 months. Started Oct 2021; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04695106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695106.